Slide Show: Bone Metastases

Slideshow

This slide show features images of diffuse osteoblastic bone metastases in a 70-year-old advanced prostate cancer patient, bone metastases in the vertebral column of a kidney cancer patient, and more.

slideshow image

Slide 1: Sodium fluoride PET/CT Scan of a bone metastasis of kidney cancer; the PET scan shows the metabolic reaction of the bone.

Recent Videos
Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging
Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
ProstACT GLOBAL Results May Support “Open” Decisions in Metastatic CRPC
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Leveraging Beta and Alpha Emitters in Metastatic CRPC Management
4 experts in this video
Key Takeaways and Future Perspectives: PSMA PET Imaging in Prostate Cancer
4 experts in this video
Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
4 experts in this video
Case Discussion: Integrating PSMA PET for Focal Boost Optimization
4 experts in this video
Utilizing PSMA PET Imaging in Metastatic Prostate Cancer to Guide Treatment Strategies
4 experts in this video
Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights
4 experts in this video
Role of PSMA PET Imaging in Guiding Surgical Treatment Decisions in Prostate Cancer
177Lu Marks Practice-Changing Approval in Metastatic CRPC
177Lu Marks Practice-Changing Approval in Metastatic CRPC
Related Content
Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Tony Berberabe, MPH
June 4th 2025
Article

The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer

Roman Fabbricatore
June 3rd 2025
Article

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
April 15th 2025
Podcast

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Addition of SBRT to Nivolumab/Ipilimumab Does Not Improve Response in mCRPC

Addition of SBRT to Nivolumab/Ipilimumab Does Not Improve Response in mCRPC

Ariana Pelosci
June 2nd 2025
Article

SBRT did not significantly impact response when added to nivolumab/ipilimumab for patients with mCRPC.

Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Tim Cortese
May 29th 2025
Article

Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.